| Variables | Frequency, n (%) | Total (n = 145) | |
| Death (n = 19) | Censored (n = 126) | ||
| BMI (Kg/m2) |
|
|
|
| ≤18.5 | 08 (14.29) | 48 (85.71) | 56 (38.62) |
| >18.5 | 11 (12.36) | 78 (87.64) | 89 (61.38) |
| CD4 cells count (µL) |
|
|
|
| <50 | 06 (42.86) | 08 (57.14) | 14 (09.66) |
| 51 - 200 | 03 (08.57) | 32 (91.43) | 35 (24.14) |
| 201 - 350 | 04 (09.76) | 37 (90.24) | 41 (28.27) |
| >350 | 06 (10.91) | 49 (89.09) | 55 (37.93) |
| WHO clinical staging |
|
|
|
| Stage I | 03 (12.50) | 21 (87.50) | 24 (16.55) |
| Stage II | 00 (00.00) | 09 (100.00) | 09 (06.21) |
| Stage III | 11 (10.68) | 92 (89.32) | 103 (71.03) |
| Stage IV | 05 (07.69) | 04 (92.31) | 09 (06.21) |
| Anemia |
|
|
|
| Yes | 16 (18.18) | 72 (81.82) | 88 (60.69) |
| No | 03 (05.26) | 54 (94.74) | 57 (39.31) |
| Opportunistic infections |
|
|
|
| Yes | 12 (21.43) | 44 (78.57) | 56 (38.62) |
| No | 07 (07.87) | 82 (92.13) | 89 (61.38) |
| Co-infection TB/HIV |
|
|
|
| Yes | 06 (19.35) | 25 (80.65) | 31 (21.38) |
| No | 13 (11.40) | 101 (88.60) | 114 (78.62) |
| Therapeutic plan change |
|
|
|
| Yes | 01 (04.17) | 23 (95.83) | 24 (16.55) |
| No | 18 (14.88) | 103 (85.12) | 121 (83.45) |
| Years on treatment |
|
|
|
| 1 | 09 (45.00) | 11 (55.00) | 20 (13.79) |
| 2 - 3 | 06 (24.00) | 19 (76.00) | 25 (17.24) |
| 4 - 6 | 04 (04.00) | 96 (96.00) | 100 (68.97) |
| ART adherence |
|
|
|
| Yes | 06 (25.00) | 24 (75.00) | 32 (22.07) |
| No | 05 (05.32) | 89 (94.68) | 94 (64.83) |
| Not applicable | 08 (42.11) | 11 (57.89) | 19 (13.10) |